Share This Page
Drug Price Trends for BYETTA
✉ Email this page to a colleague
Average Pharmacy Cost for BYETTA
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| BYETTA 5 MCG DOSE PEN INJ | 00310-6512-01 | 681.26259 | ML | 2025-02-19 |
| BYETTA 10 MCG DOSE PEN INJ | 00310-6524-01 | 340.10136 | ML | 2025-02-19 |
| BYETTA 5 MCG DOSE PEN INJ | 00310-6512-01 | 680.39555 | ML | 2025-01-22 |
| BYETTA 10 MCG DOSE PEN INJ | 00310-6524-01 | 340.05506 | ML | 2025-01-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Byetta (Exenatide BID)
Overview of Byetta
Byetta, also known as exenatide BID, was the first GLP-1 (glucagon-like peptide-1) receptor agonist approved for the treatment of type 2 diabetes. Developed by Amylin Pharmaceuticals and initially marketed jointly by Amylin and Eli Lilly, Byetta was launched in 2005. Following the termination of their collaboration in 2011, the commercialization responsibilities were gradually transferred to Amylin, which was later acquired by Bristol-Myers Squibb and AstraZeneca in 2012[1].
Market Landscape of Type 2 Diabetes
The type 2 diabetes market is characterized by a high prevalence of the disease and a crowded landscape with numerous treatment options, including generics and branded drugs. Despite the maturity of the market, it is expected to undergo significant growth driven by the increasing prevalence of type 2 diabetes and the adoption of combination therapies and novel branded drugs[1].
Sales Forecast for Byetta
Historical sales data and forecasts indicate that Byetta, although not the dominant player in the GLP-1 market, has maintained a significant presence. Sales forecasts from 2012 to 2022 showed growth, particularly in key markets such as the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India, and China[1].
Current Market Trends and Projections
Global GLP-1 Market Growth
The global GLP-1 receptor agonist market, which includes Byetta, is projected to grow substantially. As of 2024, the market size is estimated to be around $49.3 billion and is expected to reach $157.5 billion by 2035, growing at a CAGR of 11.1% during the forecast period[3].
Cost Dynamics and Pricing
The cost of antidiabetic medications, including GLP-1 receptor agonists like Byetta, has been increasing significantly. From 2023 to 2024, a 23.7% increase in the gross cost of antidiabetic medications for commercial payers is projected, despite reductions in insulin prices. The unit cost of GLP-1 receptor agonists has seen a notable rise, from $1.56 in 2016 to $23.58 in 2024[2].
Impact of Rebates and Pricing Concessions
Manufacturer rebates and other pricing concessions play a crucial role in reducing the net costs for plan sponsors. However, these rebates do not always translate to lower costs for the end-users, as pharmacy benefit managers (PBMs) may retain some of these rebates to boost their profits. This complexity in pricing dynamics can affect the overall cost and accessibility of Byetta and other GLP-1 agonists[2][5].
Competitive Landscape
Byetta operates in a competitive market with several other GLP-1 receptor agonists. The market competition is expected to increase, particularly with the emergence of new therapies and the growing recognition of GLP-1 agonists as effective treatments for both type 2 diabetes and obesity. This competition may lead to downward pressure on prices, potentially through increased rebates and other pricing concessions[3][5].
SWOT Analysis
A SWOT analysis of Byetta highlights several key points:
- Strengths: Byetta was the first GLP-1 receptor agonist approved, giving it a first-mover advantage. It has a well-established safety and efficacy profile.
- Weaknesses: The drug faces intense competition from newer GLP-1 agonists and other antidiabetic medications. The transfer of commercialization responsibilities and changes in ownership have also presented challenges.
- Opportunities: The growing prevalence of type 2 diabetes and obesity presents significant market opportunities. The drug's use in combination therapies and its potential for weight management are additional growth areas.
- Threats: The market is highly competitive, and the drug's patents are subject to expiry, which could lead to generic competition. Regulatory changes and pricing pressures also pose significant threats[1][4].
Regulatory and Patent Considerations
Byetta's patent expiry timeline and market exclusivity details are critical for understanding its future market position. The drug's patents and regulatory milestones by region are essential for planning developmental timelines and generic strategies[4].
Conclusion
Byetta, as a pioneering GLP-1 receptor agonist, continues to play a significant role in the treatment of type 2 diabetes despite the increasingly competitive landscape. The market is expected to grow substantially, driven by the rising prevalence of the disease and the adoption of novel therapies. However, the drug's pricing and accessibility will be influenced by complex dynamics involving manufacturer rebates, PBM practices, and regulatory changes.
Key Takeaways
- Byetta was the first GLP-1 receptor agonist approved for type 2 diabetes.
- The global GLP-1 market is projected to grow significantly, reaching $157.5 billion by 2035.
- The cost of GLP-1 agonists, including Byetta, is increasing, with a 23.7% projected increase in gross costs from 2023 to 2024.
- Manufacturer rebates and PBM practices significantly impact the net costs of these medications.
- Byetta faces intense competition but has opportunities for growth in combination therapies and weight management.
FAQs
Q: What is Byetta, and when was it approved? Byetta, also known as exenatide BID, is a GLP-1 receptor agonist approved for the treatment of type 2 diabetes. It was approved and launched in 2005.
Q: Who developed and marketed Byetta initially? Byetta was developed by Amylin Pharmaceuticals and initially marketed jointly by Amylin and Eli Lilly.
Q: What are the key drivers of the growth in the type 2 diabetes market? The key drivers include the increasing prevalence of type 2 diabetes and the adoption of combination therapies and novel branded drugs.
Q: How is the global GLP-1 market expected to grow? The global GLP-1 market is expected to grow from $49.3 billion in 2024 to $157.5 billion by 2035, at a CAGR of 11.1%.
Q: What impact do manufacturer rebates have on the cost of Byetta and other GLP-1 agonists? Manufacturer rebates can significantly reduce the net costs for plan sponsors, but PBMs may retain some of these rebates, affecting the final cost to the end-users.
Sources
- Research and Markets: "Byetta (Type 2 Diabetes) - Forecast and Market Analysis to 2022" - Business Wire.
- Milliman: "Understanding the cost dynamics of antidiabetic medications" - Milliman.
- Roots Analysis: "GLP-1 Market Size, Share, Growth Report [2035]" - Roots Analysis.
- ResearchAndMarkets.com: "Byetta - Drug Insight, 2019" - ResearchAndMarkets.com.
- Segal: "New Drugs for Weight Loss What Plan Sponsors Need to Know" - Segal.
More… ↓
